Rubello D, Pozzan G B, Casara D, Girelli M E, Boccato S, Rigon F, Baccichetti C, Piccolo M, Betterle C, Busnardo B
Thyroid Center, General Hospital, Padova, Italy.
J Endocrinol Invest. 1995 Jan;18(1):35-40. doi: 10.1007/BF03349694.
Pathogenesis, natural course and therapeutic management of subclinical hypothyroidism (SH) in Down's syndrome (DS) remain object of debate in literature. In the present study thyroid function, antithyroid antibody (ATA) prevalence and serum lipid concentrations were investigated in a group of 344 Down patients (DP) and data were compared with those obtained from a control group of 257 age and sex matched healthy subjects. Thyroid function and ATA prevalence were also studied in 120 parents of DP. SH prevalence was clearly higher in DP (32.5% of cases) than in controls (1.1%) and parents (0%). Similarly, ATA prevalence was higher in DP (18% of cases) than in controls (5.8%) and parents (6.6%). In spite of this, no correlation was found in DP between SH and ATA prevalences, since ATA were detected in 18.7% of SH-DP and in 15.8% of euthyroid DP. Thus, circulating ATA were not detected in the majority of SH-DP. No significant differences regarding T4, FT4, T3 and serum lipid levels among SH and euthyroid DP and controls were found. Moreover, TSH levels were only slightly increased, generally less than 10 microU/ml, in most cases of SH-DP. Follow-up was longer than 24 months (range 2-7 years, mean 3.1) in a group of 201 DP: two different patterns of SH course were observed, mainly depending on the presence or the absence of circulating ATA. In particular, 35.7% of ATA-positive SH-DP developed a clinically evident thyroid disease (overt hypothyroidism or hyperthyroidism), while no similar case was recorded among ATA-negative SH-DP.(ABSTRACT TRUNCATED AT 250 WORDS)
唐氏综合征(DS)中亚临床甲状腺功能减退(SH)的发病机制、自然病程及治疗管理在文献中仍是争议的焦点。在本研究中,对一组344例唐氏患者(DP)的甲状腺功能、抗甲状腺抗体(ATA)患病率及血脂浓度进行了调查,并将数据与257名年龄和性别匹配的健康对照者的结果进行比较。还对120名DP的父母进行了甲状腺功能和ATA患病率研究。DP中SH患病率(32.5%)明显高于对照组(1.1%)和父母组(0%)。同样,DP中ATA患病率(18%)高于对照组(5.8%)和父母组(6.6%)。尽管如此,DP中SH与ATA患病率之间未发现相关性,因为在18.7%的SH-DP和15.8%的甲状腺功能正常的DP中检测到ATA。因此,大多数SH-DP未检测到循环ATA。SH-DP、甲状腺功能正常的DP及对照组之间在T4、FT4、T3和血脂水平方面未发现显著差异。此外,大多数SH-DP患者的促甲状腺激素(TSH)水平仅略有升高,一般低于10微单位/毫升。对一组201例DP进行了超过24个月(范围2 - 7年,平均3.1年)的随访:观察到两种不同的SH病程模式,主要取决于是否存在循环ATA。特别是,35.7%的ATA阳性SH-DP发展为临床明显的甲状腺疾病(显性甲状腺功能减退或甲状腺功能亢进),而ATA阴性的SH-DP中未记录到类似病例。(摘要截断于250字)